Advertisement

Loading...

Curaleaf Holdings, Inc.

CURA.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
$5.22
$0.44(9.21%)
Canadian Market opens in 14h 53m

Curaleaf Holdings, Inc. Fundamental Analysis

Curaleaf Holdings, Inc. (CURA.CN) shows weak financial fundamentals with a PE ratio of -13.71, profit margin of -21.47%, and ROE of -24.04%. The company generates $1.4B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.14

Areas of Concern

ROE-24.04%
Operating Margin0.21%
Cash Position3.53%
We analyze CURA.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -31.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-31.0/100

We analyze CURA.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

CURA.CN struggles to generate sufficient returns from assets.

ROA > 10%
-7.25%

Valuation Score

Excellent

CURA.CN trades at attractive valuation levels.

PE < 25
-13.71
PEG Ratio < 2
-0.14

Growth Score

Weak

CURA.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

CURA.CN shows balanced financial health with some risks.

Debt/Equity < 1
1.21
Current Ratio > 1
1.47

Profitability Score

Weak

CURA.CN struggles to sustain strong margins.

ROE > 15%
-2403.60%
Net Margin ≥ 15%
-21.47%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is CURA.CN Expensive or Cheap?

P/E Ratio

CURA.CN trades at -13.71 times earnings. This suggests potential undervaluation.

-13.71

PEG Ratio

When adjusting for growth, CURA.CN's PEG of -0.14 indicates potential undervaluation.

-0.14

Price to Book

The market values Curaleaf Holdings, Inc. at 3.32 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.32

EV/EBITDA

Enterprise value stands at 13.23 times EBITDA. This signals the market has high growth expectations.

13.23

How Well Does CURA.CN Make Money?

Net Profit Margin

For every $100 in sales, Curaleaf Holdings, Inc. keeps $-21.47 as profit after all expenses.

-21.47%

Operating Margin

Core operations generate 0.21 in profit for every $100 in revenue, before interest and taxes.

0.21%

ROE

Management delivers $-24.04 in profit for every $100 of shareholder equity.

-24.04%

ROA

Curaleaf Holdings, Inc. generates $-7.25 in profit for every $100 in assets, demonstrating efficient asset deployment.

-7.25%

Following the Money - Real Cash Generation

Operating Cash Flow

Curaleaf Holdings, Inc. generates limited operating cash flow of $135.97M, signaling weaker underlying cash strength.

$135.97M

Free Cash Flow

Curaleaf Holdings, Inc. produces free cash flow of $50.78M, offering steady but limited capital for shareholder returns and expansion.

$50.78M

FCF Per Share

Each share generates $0.07 in free cash annually.

$0.07

FCF Yield

CURA.CN converts 1.21% of its market value into free cash.

1.21%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.71

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.14

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.32

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.03

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.21

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.47

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.24

vs 25 benchmark

ROA

Return on assets percentage

-0.07

vs 25 benchmark

ROCE

Return on capital employed

0.001

vs 25 benchmark

How CURA.CN Stacks Against Its Sector Peers

MetricCURA.CN ValueSector AveragePerformance
P/E Ratio-13.7128.31 Better (Cheaper)
ROE-24.04%699.00% Weak
Net Margin-21.47%-131318.00% (disorted) Weak
Debt/Equity1.210.34 Weak (High Leverage)
Current Ratio1.472775.16 Neutral
ROA-7.25%-14513.00% (disorted) Weak

CURA.CN outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Curaleaf Holdings, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ